The current study was conducted to evaluate the effect of IL-15 in combination with the ADU-S100 analog 2’3’-c-di-AM(PS)2 (Rp,Rp) as immunotherapeutic agents for the treatment of prostate cancer. The gene discussed is IL15; the disease is prostate carcinoma.